Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder

被引:24
作者
Martin-Blanco, A. [1 ,2 ,3 ,4 ]
Ancochea, A. [1 ,2 ,3 ,4 ]
Soler, J. [1 ,2 ,3 ,4 ]
Elices, M. [1 ,2 ,3 ,4 ]
Carmona, C. [1 ,2 ,3 ,4 ]
Pascual, J. C. [1 ,2 ,3 ,4 ]
机构
[1] Santa Creu & St Pau Hosp, Dept Psychiat, Ave St Antoni Ma Claret 167, Barcelona 08025, Spain
[2] Autonomous Univ Barcelona, Barcelona, Spain
[3] Santa Creu & St Pau Hosp IIB St Pau, Res Inst, Barcelona, Spain
[4] CIBERSAM, CIBER Mental Hlth CIBERSAM, Barcelona, Spain
关键词
personality disorder; treatment; psychopharmacology; II COMPARISON SUBJECTS; PSYCHOTROPIC MEDICATION; FOLLOW-UP; TRIALS; PHARMACOTHERAPY; VERSION;
D O I
10.1111/acps.12767
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Objective: To describe the pharmacological management of borderline personality disorder (BPD) in Spain from 2001 through 2016, the factors associated with prescriptions, and changes in pharmacotherapy over this time period. Methods: Retrospective, cross-sectional, observational study conducted in a sample of 457 patients with BPD consecutively admitted to a specialist BPD Program between January 2001 and November 2016. Data on sociodemographic and clinical variables, as well as pharmacological treatment upon the admission to the programme, were used to describe pharmacological prescriptions, the factors associated with these medications, and changes in prescription over the last 15 years. Results: Most (88.4%) patients were on pharmacological treatment, with 53.8% of persons taking >= 3 medications. No significant changes in these percentages were observed over the study period. The use of tricyclic antidepressants and benzodiazepines decreased, while the use of atypical antipsychotics increased. Axis I comorbidity was the main factor associated with pharmacological treatment and polypharmacy. Conclusions: This study provides further evidence confirming the worldwide overuse of prescription medications for BPD and shows that there has been a shift in the prescription pattern in the last 15 years. These results suggest that real clinical practice only partially adheres to clinical treatment guidelines.
引用
收藏
页码:323 / 331
页数:9
相关论文
共 22 条
[1]  
[Anonymous], 2012, Clinical practice guideline for the management of borderline personality disorder
[2]  
[Anonymous], MULT RICHTL DIAGN BE
[3]  
Barrachina J, 2004, ACTAS ESP PSIQUIATRI, V32, P293
[4]   Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders [J].
Bridler, Rene ;
Haeberle, Anne ;
Mueller, Sabrina T. ;
Cattapan, Katja ;
Grohmann, Renate ;
Toto, Sermin ;
Kasper, Siegfried ;
Greil, Waldemar .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 (06) :763-772
[5]  
Codony M, 2007, Actas Esp Psiquiatr, V35 Suppl 2, P29
[6]   Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting [J].
Crawford, M. J. ;
Kakad, S. ;
Rendel, C. ;
Mansour, N. A. ;
Crugel, M. ;
Liu, K. W. ;
Paton, C. ;
Barnes, T. R. E. .
ACTA PSYCHIATRICA SCANDINAVICA, 2011, 124 (05) :396-402
[7]  
DGPPN. Deutsche Gesellschaft fur Psychiatry Psychotherapie und Nervenheilkunde, 2009, BEH PERS
[8]   State of the Art in the Pharmacologic Treatment of Borderline Personality Disorder [J].
Feurino, Louis, III ;
Silk, Kenneth R. .
CURRENT PSYCHIATRY REPORTS, 2011, 13 (01) :69-75
[9]   Empirical evidence and psychotherapy: A growing scientific base [J].
Gabbard, GO .
AMERICAN JOURNAL OF PSYCHIATRY, 2001, 158 (01) :1-3
[10]   THE DIAGNOSIS OF PERSONALITY-DISORDER WITH A MODIFIED VERSION OF THE SCID-II IN A SPANISH CLINICAL-SAMPLE [J].
GOMEZBENEYTO, M ;
VILLAR, M ;
RENOVELL, M ;
PEREZ, F ;
HERNANDEZ, M ;
LEAL, C ;
CUQUERELLA, M ;
SLOK, C ;
ASENCIO, A .
JOURNAL OF PERSONALITY DISORDERS, 1994, 8 (02) :104-110